Assessment of liver function for safe hepatic resection

Hepatology Research

Volumn 39, Issue 2, 2009, Pages 107-116

  Seyama, Yasuji ^a   Kokudo, Norihiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Indocyanine green; Liver function test; Postoperative liver failure; TcGSA

Indexed keywords

GALACTOSE; GALACTOSYL HUMAN SERUM ALBUMIN PENTETIC ACID; INDOCYANINE GREEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTIFICIAL EMBOLISM; BREATH ANALYSIS; DRUG ELIMINATION; FUNCTIONAL ASSESSMENT; HUMAN; INTERMETHOD COMPARISON; LIVER FAILURE; LIVER FUNCTION TEST; LIVER PERFUSION; LIVER RESECTION; LIVER SCINTISCANNING; LIVER WEIGHT; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SURGICAL MORTALITY; SURGICAL RISK; SURGICAL TECHNIQUE; TREATMENT INDICATION;

EID: 59149104137     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00441.x     Document Type: Review

References (59)

1. Okamoto E, Kyo A, Yamanaka N, Tanaka N, Kuwata K. Prediction of the safe limits of hepatectomy by combined volumetric and functional measurements in patients with impaired hepatic function. Surgery 1984; 95: 586-92.
2. Franco D, Capussotti L, Smadja C et al. Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis. Gastroenterology 1990; 98: 733-8.
3. Makuuchi M, Kosuge T, Takayama T et al. Surgery for small liver cancers. Semin Surg Oncol 1993; 9: 298-304.
4. Fan ST, Lai EC, Lo CM, Ng IO, Wong J. Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch Surg 1995; 130: 198-203.
5. Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-72.
6. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94: 274-86.
7. Child CG, Turcotte JC. Surgery and portal hypertension. In: Child CG, ed. The Liver and Portal Hypertension. Philadelphia, PA: Saunders, 1964; 50-1.
8. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
9. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-71.
10. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
11. Zimmermann H, Reichen J.. Assessment of the liver function in the surgical patient. In: Blumgart LH, Fong Y, eds. Surgery of the liver and biliary tract. London: Saunders, 2000; 35-64.
12. Hemming AW, Scudamore CH, Shackleton CR, Pudek M, Erb SR. Indocyanine green clearance as a predictor of successful hepatic resection in cirrhotic patients. Am J Surg 1992; 163: 515-18.
13. Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatectomies without mortality in 8years. Arch Surg 2003; 138: 1198-206 [discussion 1206].
14. Schroeder RA, Marroquin CE, Bute BP, Khuri S, Henderson WG, Kuo PC. Predictive indices of morbidity and mortality after liver resection. Ann Surg 2006; 243: 373-9.
15. Teh SH, Sheppard BC, Schwartz J, Orloff SL. Model for End-stage Liver Disease score fails to predict perioperative outcome after hepatic resection for hepatocellular carcinoma in patients without cirrhosis. Am J Surg 2008; 195: 697-701.
16. Pimstone NR, Stadalnik RC, Vera DR, Hutak DP, Trudeau WL. Evaluation of hepatocellular function by way of receptor-mediated uptake of a technetium-99m-labeled asialoglycoprotein analog. Hepatology 1994; 20: 917-23.
17. Mahmoud M, Abdel-Kader R, Hassanein M, Saleh S, Botros S. Antipyrine clearance in comparison to conventional liver function tests in hepatitis C virus patients. Eur J Pharmacol 2007; 569: 222-7.
18. Huo TI, Lin HC, Wu JC et al. Proposal of a modified Child-Turcotte-Pugh scoring system and comparison with the model for end-stage liver disease for outcome prediction in patients with cirrhosis. Liver Transpl 2006; 12: 65-71.
19. Wiesner R, Edwards E, Freeman R et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-6.
20. Teh SH, Christein J, Donohue J et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg 2005; 9: 1207-15 [discussion 1215].
21. Cucchetti A, Ercolani G, Cescon M et al. Recovery from liver failure after hepatectomy for hepatocellular carcinoma in cirrhosis: Meaning of the model for end-stage liver disease. J Am Coll Surg 2006; 203: 670-6.
22. Miyagawa S, Makuuchi M, Kawasaki S, Kakazu T. Criteria for safe hepatic resection. Am J Surg 1995; 169: 589-94.
23. Imamura H, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Assessment of hepatic reserve for indication of hepatic resection: Decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg 2005; 12: 16-22.
24. Kobayashi T, Imamura H, Takayama T, Makuuchi M. The role of preoperative phenylalanine breath test in hepatectomy. Hepatogastroenterology 2003; 50: 1124-7.
25. Goetze O, Selzner N, Fruehauf H, Fried M, Gerlach T, Mullhaupt B. 13C-methacetin breath test as a quantitative liver function test in patients with chronic hepatitis C infection: Continuous automatic molecular correlation spectroscopy compared to isotopic ratio mass spectrometry. Aliment Pharmacol Ther 2007; 26: 305-11.
26. Lau H, Man K, Fan ST, Yu WC, Lo CM, Wong J. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg 1997; 84: 1255-9.
27. Makuuchi M, Kokudo N, Arii S et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in. Japan. Hepatol Res 2008; 38: 37-51.
28. Nonami T, Harada A, Kurokawa T, Nakao A, Takagi H. Hepatic resection for hepatocellular carcinoma. Am J Surg 1997; 173: 288-91.
29. Kubota K, Makuuchi M, Kusaka K et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 1997; 26: 1176-81.
30. Shirabe K, Shimada M, Gion T et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg 1999; 188: 304-9.
31. Makuuchi M, Thai BL, Takayasu K et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: A preliminary report. Surgery 1990; 107: 521-7.
32. Imamura H, Shimada R, Kubota M et al. Preoperative portal vein embolization: An audit of 84 patients. Hepatology 1999; 29: 1099-105.
33. Torizuka K, Ha-Kawa SK, Ikekubo K et al. [Phase I clinical study on 99mTc-GSA, a new agent for functional imaging of the liver]. Kaku Igaku 1991; 28: 1321-31. (In Japanese.)
34. Torizuka K, Ha-Kawa SK, Kudo M et al. Phase II clinical study on 99mTc-GSA, a new agent for functional imaging of the liver. Kaku Igaku 1992; 29: 85-95.
35. Nanashima A, Yamaguchi H, Shibasaki S et al. Relationship between indocyanine green test and technetium-99m galactosyl serum albumin scintigraphy in patients scheduled for hepatectomy: Clinical evaluation and patient outcome. Hepatol Res 2004; 28: 184-90.
36. Vera DR, Stadalnik RC, Trudeau WL, Scheibe PO, Krohn KA. Measurement of receptor concentration and forward-binding rate constant via radiopharmacokinetic modeling of technetium-99m-galactosyl-neoglycoalbumin. J Nucl Med 1991; 32: 1169-76.
37. Ha-Kawa SK, Tanaka Y. A quantitative model of technetium-99m-DTPA-galactosyl-HSA for the assessment of hepatic blood flow and hepatic binding receptor. J Nucl Med 1991; 32: 2233-40.
38. Miki K, Kubota K, Kokudo N, Inoue Y, Bandai Y, Makuuchi M. Asialoglycoprotein receptor and hepatic blood flow using technetium-99m-DTPA-galactosyl human serum albumin. J Nucl Med 1997; 38: 1798-807.
39. Kokudo N, Vera DR, Koizumi M et al. Recovery of hepatic asialoglycoprotein receptors after major hepatic resection. J Nucl Med 1999; 40: 137-41.
40. Kwon AH, Matsui Y, Kaibori M, Ha-Kawa SK. Preoperative regional maximal removal rate of technetium-99m-galactosyl human serum albumin (GSA-Rmax) is useful for judging the safety of hepatic resection. Surgery 2006; 140: 379-86.
41. Kokudo N, Vera DR, Makuuchi M. Clinical application of TcGSA. Nucl Med Biol 2003; 30: 845-9.
42. Kokudo N, Vera DR, Tada K et al. Predictors of successful hepatic resection: Prognostic usefulness of hepatic asialoglycoprotein receptor analysis. World J Surg 2002; 26: 1342-7.
43. Redaelli CA, Dufour JF, Wagner M et al. Preoperative galactose elimination capacity predicts complications and survival after hepatic resection. Ann Surg 2002; 235: 77-85.
44. Jochum C, Beste M, Penndorf V et al. Quantitative liver function tests in donors and recipients of living donor liver transplantation. Liver Transpl 2006; 12: 544-9.
45. Finch MD, Crosbie JL, Currie E, Garden OJ. An 8-year experience of hepatic resection: Indications and outcome. Br J Surg 1998; 85: 315-19.
46. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: An update to evaluate the actual risk of liver resection. J Am Coll Surg 2000; 191: 38-46.
47. Mullen JT, Ribero D, Reddy SK et al. Hepatic insufficiency and mortality in 1059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 2007; 204: 854-62 [discussion 862-4].
48. Bruix J, Castells A, Bosch J et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure. Gastroenterology 1996; 111: 1018-22.
49. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
50. Ikai I, Arii S, Ichida T et al. Report of the 16th follow-up survey of primary liver cancer. Hepatol Res 2005; 32: 163-72.
51. Liver Caner Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 2nd ed. Tokyo: Kanehara; 2003.
52. Saito S, Yamanaka J, Miura K et al. A novel 3D hepatectomy simulation based on liver circulation: Application to liver resection and transplantation. Hepatology 2005; 41: 1297-304.
53. Satou S, Sugawara Y, Tamura S et al. Three-dimensional computed tomography for planning donor hepatectomy. Transplant Proc 2007; 39: 145-9.
54. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200: 845-53.
55. Vauthey JN, Chaoui A, Do KA et al. Standardized measurement of the future liver remnant prior to extended liver resection: Methodology and clinical associations. Surgery 2000; 127: 512-19.
56. Seyama Y, Kubota K, Sano K et al. Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann Surg 2003; 238: 73-83.
57. Aoki T, Imamura H, Hasegawa K et al. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg 2004; 139: 766-74.
58. Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 2007; 94: 1386-94.
59. Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007; 356: 1545-59.